News

Erika P. Hamilton, MD, discusses the key safety and efficacy findings from the phase 3 DESTINY-Breast03 study.

In an interview with Targeted Oncology, Karie Runcie, MD, provided an assessment on the Clavien-Dindo classification system and discussed initial results of the Cyo-KIK trial.

Updated data from the phase 3 CheckMate 9LA trial showed that the combination of nivolumab, ipilimumab, and 2 cycles of chemotherapy elicited survival benefit in patients with treatment-naïve metastatic non–small cell lung cancer.

An analysis of data from 2002-2015 shows that for patients with mantle cell lymphoma achieving event-free survival after two years may be a prognostic factor for better overall survival outcomes.

The FDA has approved a new dosing schedule of Rylaze for patients with acute lymphoblastic leukemia and lymphoblastic lymphoma.

DCVax-L was well tolerated and prolonged survival in patients with newly diagnosed and recurrent glioblastoma within the phase 3 trial.

An investigational agent is planned for a phase 1 trial of patients with mantle cell lymphoma after preclinical data showed antitumor activity.

Real-world evidence from Florida Cancer Specialists & Research Institute shows that trilaciclib may reduce the chance of chemotherapy-induced myelosuppression events in patients with extensive-stage small cell lung cancer.

In patients with non–small cell lung cancer who harbor an EGFR exon 20 insertion mutation, sunvozertinib demonstrated promising efficacy.

Mark R. Litzow, MD, discusses the talk he gave on initial treatment options for patients with acute lymphoblastic leukemia during the National Comprehensive Cancer Network 2022 Annual Congress: Hematologic Malignancies.

Updated results of the EMPOWER-Lung1 trial of cemiplimab in patients advanced or metastatic non–small cell lung cancer showed improvements in overall survival, progression-free survival, and overall response rate.

Fifty percent of patients with advanced soft tissue sarcoma enrolled in the phase 1b study of camsirubicin and pegfilgrastim had stable disease.

Tepotinib was able to provide clinically meaningful activity in patients with high MET amplification non–small cell lung cancer in the VISION study, according to Xiuning Le, MD, PhD.

Initial results from the phase 3 spotlight study show that the study met its primary and key secondary end point of progression-free and overall survival.

The combination of ivuxolimab and utomilumab was well tolerated in patients with advanced solid tumors, according to a phase 1 study.

In an interview with Targeted Oncology, Nagaraj Nagathihalli, PhD, further explained the basis behind his study examining tobacco-associated pancreatic cancer and his plans to improve overall survival in this patient population.

Eytan M. Stein, MD, discusses the currently available treatment options for patients with acute myeloid leukemia and how Menin inhibitors fit into this space.

Findings from the phase 2 TheraP trial showed 177Lu-PSMA-617 to result in a higher prostate-specific antigen response rate vs with cabazitaxel in patients with metastatic castration-resistant prostate cancer.

While information has come out stating the negative effects of e-cigarettes on lung health, questions regarding the longer-term safety of these products remain due to their limited timespan on the market.

Fruquintinib plus paclitaxel demonstrated improvements in progression-free survival, objective response rate, disease control rate, and more, in patients with advanced gastric or gastroesophageal junction adenocarcinoma.

Cyrus M. Kahn, MD, discusses the evolution of the treatment landscape for patients with mantle cell lymphoma.

Robert J. Soiffer, MD, discusses the use of transplant in various hematologic malignancies.

Randomized studies examining patients with peripheral T-cell lymphoma regarding the role of transplant are lacking and more research is needed to personalize therapy for patients based on subtype, biomarkers, mutational profiling, and radiographic parameters.

The new VENTANA FOLR1 RxDx Assay has been approved by the FDA and will aid in identifying patients with ovarian cancer who are eligible for targeted treatment with mirvetuximab soravtansine.

With the addition of eganelisib to atezolizumab plus nab-paclitaxel, patients with metastatic triple negative breast cancer have longer progression-free survival and better response vs atezolizumab and nab-paclitaxel alone.

A phase 1 trial evaluating 5-aminolevulinic acid and CV01 delivery of ultrasound has begun treating the first 3 of approximately 33 patients with recurrent high-grade glioma.

Treatment with CUE-101 continued to show promise for patients with head and neck squamous cell carcinoma when combined with pembrolizumab or used as a monotherapy.

Michael Diaz, MD, will participate as a panelist for the Patient-Centered Oncology Care conference presented by The American Journal of Managed Care on November 9 – 10, 2022 in Nashville, TN.

Mirvetuximab soravtansine has been granted FDA accelerated approval for use in patients with folate receptor alpha-high platinum-resistant ovarian cancer who have received prior treatment with 1 to 3 prior systemic therapies.

Alexander Spira, MD, PhD, FACP, discusses the rationale for combining amivantamab-vmjw and lazertinib for the treatment of relapsed or refractory EGFR-mutant non–small cell lung cancer.